Compare Sanofi SA (SNY) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs VF Corp — how do they compare? Sanofi SA trades at $40.07 (market cap $95.18B), while VF Corp trades at $15 (market cap $5.71B). The key difference: Sanofi SA is far larger — about 16.7× VF Corp's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and VF Corp for 65 Days on average.
| SNY | VFC | |
|---|---|---|
Market Cap | $95.18B | $5.71B |
Volume | 2,995,646 | 8,987,330 |
Sector | Health | Consumer Cyclical |
52-Week High | $52.34 | $21.55 |
52-Week Low | $39.51 | $12.62 |
Typical Hold Time | 94 Days | 65 Days |
Enterprise Value | $114.48B | $10.00B |
Dividend Yield | 6.01% | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
VFC trades at $15.00, up 4.31% today, with a bullish technical signal from moving averages and oscillators. The company reported mixed quarterly results, beating in Q4 2025 but missing in subsequent quarters, with revenue declining from $11.8B in 2022 to $9.5B in 2025. Analyst consensus is a 'Hold' with a $18.33 price target, representing 22% upside potential from current levels.
VFC faces execution challenges with Vans brand weakness offsetting strength in Outdoor segments, though valuation appears attractive with P/S of 0.61. Key risks include ongoing revenue declines, negative net income, and high debt levels. The stock offers potential upside if management's turnaround plan succeeds, but requires careful monitoring of quarterly execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
